IV PERSANTINE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IV PERSANTINE is an injectable small-molecule therapeutic approved by Boehringer Ingelheim in 1990 for intravenous administration. The specific indication and mechanism of action are not documented in available data; however, the product remains actively marketed. This legacy product represents a mature franchise with evolving clinical utility.
LOE Approaching
Competitive pressure remains moderate (30%) despite approaching LOE, indicating sustained but declining commercial activity with potential team rightsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IV PERSANTINE roles are concentrated in commercial and market-access functions with zero active job openings, reflecting mature-stage maintenance activities. Careers on this asset favor defensive commercial strategy and generic-transition planning rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on IV PERSANTINE at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.